These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24614067)

  • 1. Long-term control of HIV replication with dolutegravir and pegylated interferon alpha-2a in an HIV-infected patient with sixtuple-class resistance.
    Montes ML; Schapiro J; Pérez-Valero I; García-Bujalance S; Arribas JR
    AIDS; 2014 Mar; 28(6):932-4. PubMed ID: 24614067
    [No Abstract]   [Full Text] [Related]  

  • 2. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
    Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
    Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial.
    Asmuth DM; Murphy RL; Rosenkranz SL; Lertora JJ; Kottilil S; Cramer Y; Chan ES; Schooley RT; Rinaldo CR; Thielman N; Li XD; Wahl SM; Shore J; Janik J; Lempicki RA; Simpson Y; Pollard RB;
    J Infect Dis; 2010 Jun; 201(11):1686-96. PubMed ID: 20420510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
    J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy.
    Borghetti A; Baldin G; Ciccullo A; Gagliardini R; D'Avino A; Mondi A; Ciccarelli N; Lamonica S; Fanti I; Trecarichi E; Fabbiani M; Cauda R; De Luca A; Di Giambenedetto S
    J Antimicrob Chemother; 2016 Aug; 71(8):2359-61. PubMed ID: 27147306
    [No Abstract]   [Full Text] [Related]  

  • 6. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
    Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
    J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.
    Carosi G; Bruno R; Cariti G; Nasta P; Gulminetti R; Galli M; Angarano G; Verucchi G; Pontali E; Capetti A; Raise E; Ravasio V; Maida I; Iannacone C; Caputo A; Puoti M
    Antivir Ther; 2014; 19(8):735-45. PubMed ID: 24583976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir: successful experience in a challenging patient.
    Bonadies G; Maraolo AE; Tambaro O; Palmiero G; Di Filippo G; Orlando R
    AIDS; 2015 Jun; 29(10):1269-71. PubMed ID: 26035327
    [No Abstract]   [Full Text] [Related]  

  • 9. Dolutegravir monotherapy in HIV-infected naive patients with an HIV-RNA load <100 000 copies/mL: a medium-term follow-up.
    Lanzafame M; Nicolè S; Gibellini D; Lattuada E; Cucchetto G; Rigo F; Diani E; Concia E; Vento S
    J Antimicrob Chemother; 2017 Jul; 72(7):2136-2138. PubMed ID: 28387810
    [No Abstract]   [Full Text] [Related]  

  • 10. How individual can personalized antiretroviral treatment be? Deep salvage in an HIV-1-infected patient.
    Jensen B; Esser S; Kaiser R; Luebke N; Häussinger D
    Intervirology; 2012; 55(2):167-71. PubMed ID: 22286888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HIV-naive patients respond to pegylated interferon].
    Internist (Berl); 2003 Jun; 44(6):672. PubMed ID: 14733245
    [No Abstract]   [Full Text] [Related]  

  • 12. Delaying HCV treatment in HIV-positive patients.
    Carter M
    IAPAC Mon; 2005 May; 11(5):147. PubMed ID: 16201045
    [No Abstract]   [Full Text] [Related]  

  • 13. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
    Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W
    Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
    J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia.
    Zhang RF; Sun HQ; Huang Q; Wang JR; Zhang XX; Liu XN; Ma Q; Lu HZ
    Haemophilia; 2010 May; 16(3):502-7. PubMed ID: 20028427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
    Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M
    J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft.
    Antonini TM; Furlan V; Teicher E; Haim-Boukobza S; Sebagh M; Coilly A; Bonhomme-Faivre L; Peytavin G; Roque-Afonso AM; Vittecoq D; Samuel D; Taburet AM; Duclos-Vallée JC
    AIDS; 2013 Oct; 27(16):2655-7. PubMed ID: 23939241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A world without an HIV vaccine (or, sunrise with sea monsters). 11th conference on retroviruses and opportunistic infections. February 8-11, 2004, San Francisco.
    Mascolini M
    IAPAC Mon; 2004 Apr; 10(4):114-32. PubMed ID: 15218849
    [No Abstract]   [Full Text] [Related]  

  • 19. Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice.
    Ciccullo A; Baldin G; Cossu MV; Passerini M; Borghetti A; Capetti A; Di Giambenedetto S
    AIDS Res Hum Retroviruses; 2020 Jan; 36(1):4-5. PubMed ID: 31476877
    [No Abstract]   [Full Text] [Related]  

  • 20. Association of dolutegravir and rilpivirine, enhanced by foscarnet induction, in effective salvage antiretroviral therapy.
    Leporrier J; Etienne M; Chapuzet C; Peytavin G; Bord S; Borsa-Lebas F; Caron F; Plantier JC; Mourez T
    J Clin Virol; 2014 Aug; 60(4):428-30. PubMed ID: 24932736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.